25 XP   0   0   10

Pharmicell
Buy, Hold or Sell?

Let's analyse Pharmicell together

PenkeI guess you are interested in Pharmicell. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharmicell. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pharmicell

I send you an email if I find something interesting about Pharmicell.

Quick analysis of Pharmicell (30 sec.)










What can you expect buying and holding a share of Pharmicell? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩1,339.86
Expected worth in 1 year
₩1,402.06
How sure are you?
77.3%

+ What do you gain per year?

Total Gains per Share
₩62.20
Return On Investment
1.1%

For what price can you sell your share?

Current Price per Share
₩5,550.00
Expected price per share
₩5,290 - ₩6,950
How sure are you?
50%

1. Valuation of Pharmicell (5 min.)




Live pricePrice per Share (EOD)

₩5,550.00

Intrinsic Value Per Share

₩-1,428.21 - ₩-1,684.74

Total Value Per Share

₩-88.35 - ₩-344.88

2. Growth of Pharmicell (5 min.)




Is Pharmicell growing?

Current yearPrevious yearGrowGrow %
How rich?$56.2m$54.6m$2m3.5%

How much money is Pharmicell making?

Current yearPrevious yearGrowGrow %
Making money$626.1k$1.9m-$1.2m-204.2%
Net Profit Margin6.7%16.5%--

How much money comes from the company's main activities?

3. Financial Health of Pharmicell (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#464 / 1016

Most Revenue
#304 / 1016

Most Profit
#153 / 1016

Most Efficient
#132 / 1016

What can you expect buying and holding a share of Pharmicell? (5 min.)

Welcome investor! Pharmicell's management wants to use your money to grow the business. In return you get a share of Pharmicell.

What can you expect buying and holding a share of Pharmicell?

First you should know what it really means to hold a share of Pharmicell. And how you can make/lose money.

Speculation

The Price per Share of Pharmicell is ₩5,550. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharmicell.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharmicell, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩1,339.86. Based on the TTM, the Book Value Change Per Share is ₩15.55 per quarter. Based on the YOY, the Book Value Change Per Share is ₩47.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharmicell.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.010.0%0.010.0%0.030.0%0.020.0%0.010.0%
Usd Book Value Change Per Share-0.020.0%0.010.0%0.030.0%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.020.0%0.010.0%0.030.0%0.000.0%0.000.0%
Usd Price Per Share4.25-5.23-7.78-8.57-8.03-
Price to Earnings Ratio73.84-141.29--237.91-26.60-22.26-
Price-to-Total Gains Ratio-220.27-287.36-73.03-238.33-214.49-
Price to Book Ratio4.53-5.53-8.56-11.94-11.09-
Price-to-Total Gains Ratio-220.27-287.36-73.03-238.33-214.49-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.885
Number of shares257
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.00
Usd Total Gains Per Share0.010.00
Gains per Quarter (257 shares)2.80-0.58
Gains per Year (257 shares)11.19-2.32
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101110-2-12
2022120-5-14
3034230-7-16
4045340-9-18
5056450-12-20
6067560-14-22
7078670-16-24
8090780-19-26
90101890-21-28
1001121000-23-30

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%18.02.00.090.0%18.04.00.081.8%19.05.02.073.1%
Book Value Change Per Share3.01.00.075.0%10.02.00.083.3%16.04.00.080.0%17.05.00.077.3%19.07.00.073.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.026.00.0%
Total Gains per Share3.01.00.075.0%10.02.00.083.3%16.04.00.080.0%17.05.00.077.3%19.07.00.073.1%

Fundamentals of Pharmicell

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; Hearticellgram_AMI, a cardiac disease drug; Cellgram_CKD for the treatment of chronic kidney disease; and Cellgram_AKI for the treatment of acute kidney disease. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, as well as clinical development and commercialization services for new drugs. Further, it operates Twelve, a stem cell bank; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 21:52:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Pharmicell.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharmicell earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Pharmicell to the Biotechnology industry mean.
  • A Net Profit Margin of 9.3% means that ₩0.09 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharmicell:

  • The MRQ is 9.3%. The company is making a profit. +1
  • The TTM is 6.7%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.3%TTM6.7%+2.7%
TTM6.7%YOY16.5%-9.8%
TTM6.7%5Y13.2%-6.6%
5Y13.2%10Y6.3%+7.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.3%-199.6%+208.9%
TTM6.7%-213.0%+219.7%
YOY16.5%-279.3%+295.8%
5Y13.2%-438.4%+451.6%
10Y6.3%-605.5%+611.8%
1.1.2. Return on Assets

Shows how efficient Pharmicell is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharmicell to the Biotechnology industry mean.
  • 1.3% Return on Assets means that Pharmicell generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharmicell:

  • The MRQ is 1.3%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.9%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.3%TTM0.9%+0.5%
TTM0.9%YOY2.5%-1.6%
TTM0.9%5Y2.0%-1.1%
5Y2.0%10Y1.5%+0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3%-13.5%+14.8%
TTM0.9%-12.9%+13.8%
YOY2.5%-11.8%+14.3%
5Y2.0%-14.1%+16.1%
10Y1.5%-16.0%+17.5%
1.1.3. Return on Equity

Shows how efficient Pharmicell is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharmicell to the Biotechnology industry mean.
  • 1.5% Return on Equity means Pharmicell generated ₩0.02 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharmicell:

  • The MRQ is 1.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.5%TTM1.1%+0.4%
TTM1.1%YOY3.5%-2.4%
TTM1.1%5Y2.6%-1.5%
5Y2.6%10Y2.1%+0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5%-16.9%+18.4%
TTM1.1%-16.1%+17.2%
YOY3.5%-15.1%+18.6%
5Y2.6%-19.9%+22.5%
10Y2.1%-20.9%+23.0%

1.2. Operating Efficiency of Pharmicell.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharmicell is operating .

  • Measures how much profit Pharmicell makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharmicell to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharmicell:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y6.1%-6.1%
5Y6.1%10Y0.2%+5.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y6.1%-477.4%+483.5%
10Y0.2%-625.6%+625.8%
1.2.2. Operating Ratio

Measures how efficient Pharmicell is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.73 means that the operating costs are ₩1.73 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Pharmicell:

  • The MRQ is 1.725. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.699. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.725TTM1.699+0.026
TTM1.699YOY1.478+0.220
TTM1.6995Y1.493+0.205
5Y1.49310Y1.583-0.089
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7253.090-1.365
TTM1.6993.264-1.565
YOY1.4783.783-2.305
5Y1.4935.679-4.186
10Y1.5837.894-6.311

1.3. Liquidity of Pharmicell.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharmicell is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.56 means the company has ₩5.56 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharmicell:

  • The MRQ is 5.560. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.393. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.560TTM3.393+2.168
TTM3.393YOY2.750+0.643
TTM3.3935Y5.601-2.209
5Y5.60110Y5.220+0.381
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5603.914+1.646
TTM3.3934.220-0.827
YOY2.7505.388-2.638
5Y5.6016.045-0.444
10Y5.2206.406-1.186
1.3.2. Quick Ratio

Measures if Pharmicell is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharmicell to the Biotechnology industry mean.
  • A Quick Ratio of 0.92 means the company can pay off ₩0.92 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharmicell:

  • The MRQ is 0.923. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.646. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.923TTM0.646+0.277
TTM0.646YOY1.112-0.466
TTM0.6465Y1.629-0.983
5Y1.62910Y1.534+0.095
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9233.572-2.649
TTM0.6463.998-3.352
YOY1.1125.390-4.278
5Y1.6295.969-4.340
10Y1.5346.287-4.753

1.4. Solvency of Pharmicell.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharmicell assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharmicell to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13 means that Pharmicell assets are financed with 13.1% credit (debt) and the remaining percentage (100% - 13.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharmicell:

  • The MRQ is 0.131. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.222. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.131TTM0.222-0.091
TTM0.222YOY0.280-0.058
TTM0.2225Y0.232-0.010
5Y0.23210Y0.226+0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1310.336-0.205
TTM0.2220.334-0.112
YOY0.2800.269+0.011
5Y0.2320.366-0.134
10Y0.2260.390-0.164
1.4.2. Debt to Equity Ratio

Measures if Pharmicell is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharmicell to the Biotechnology industry mean.
  • A Debt to Equity ratio of 15.1% means that company has ₩0.15 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharmicell:

  • The MRQ is 0.151. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.294. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.151TTM0.294-0.143
TTM0.294YOY0.390-0.096
TTM0.2945Y0.312-0.018
5Y0.31210Y0.301+0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1510.382-0.231
TTM0.2940.396-0.102
YOY0.3900.335+0.055
5Y0.3120.434-0.122
10Y0.3010.465-0.164

2. Market Valuation of Pharmicell

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Pharmicell generates.

  • Above 15 is considered overpriced but always compare Pharmicell to the Biotechnology industry mean.
  • A PE ratio of 73.84 means the investor is paying ₩73.84 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharmicell:

  • The EOD is 67.517. Based on the earnings, the company is expensive. -2
  • The MRQ is 73.843. Based on the earnings, the company is expensive. -2
  • The TTM is 141.293. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD67.517MRQ73.843-6.326
MRQ73.843TTM141.293-67.449
TTM141.293YOY-237.908+379.201
TTM141.2935Y26.604+114.688
5Y26.60410Y22.264+4.340
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD67.517-2.259+69.776
MRQ73.843-2.569+76.412
TTM141.293-2.664+143.957
YOY-237.908-4.120-233.788
5Y26.604-6.258+32.862
10Y22.264-6.171+28.435
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharmicell:

  • The EOD is -75.868. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -82.976. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 43.397. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-75.868MRQ-82.976+7.108
MRQ-82.976TTM43.397-126.374
TTM43.397YOY-105.250+148.647
TTM43.3975Y-188.189+231.587
5Y-188.18910Y-174.714-13.475
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-75.868-2.924-72.944
MRQ-82.976-3.246-79.730
TTM43.397-3.488+46.885
YOY-105.250-5.620-99.630
5Y-188.189-8.315-179.874
10Y-174.714-8.826-165.888
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharmicell is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.53 means the investor is paying ₩4.53 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharmicell:

  • The EOD is 4.142. Based on the equity, the company is fair priced.
  • The MRQ is 4.530. Based on the equity, the company is fair priced.
  • The TTM is 5.535. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.142MRQ4.530-0.388
MRQ4.530TTM5.535-1.005
TTM5.535YOY8.559-3.024
TTM5.5355Y11.940-6.405
5Y11.94010Y11.089+0.851
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.1421.851+2.291
MRQ4.5302.090+2.440
TTM5.5352.095+3.440
YOY8.5592.844+5.715
5Y11.9403.466+8.474
10Y11.0893.815+7.274
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Pharmicell compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---27.55715.549-277%47.129-158%-3.228-88%-1.533-94%
Book Value Per Share--1339.8591349.449-1%1301.661+3%1088.703+23%1118.864+20%
Current Ratio--5.5603.393+64%2.750+102%5.601-1%5.220+7%
Debt To Asset Ratio--0.1310.222-41%0.280-53%0.232-44%0.226-42%
Debt To Equity Ratio--0.1510.294-49%0.390-61%0.312-52%0.301-50%
Dividend Per Share----0%-0%-0%-0%
Eps--20.55014.907+38%45.350-55%27.969-27%21.301-4%
Free Cash Flow Per Share---18.28824.135-176%-46.011+152%-6.912-62%-10.217-44%
Free Cash Flow To Equity Per Share---18.28824.135-176%-46.011+152%-6.912-62%-3.252-82%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1684.736--------
Intrinsic Value_10Y_min---1428.213--------
Intrinsic Value_1Y_max---94.851--------
Intrinsic Value_1Y_min---93.123--------
Intrinsic Value_3Y_max---341.363--------
Intrinsic Value_3Y_min---324.756--------
Intrinsic Value_5Y_max---655.844--------
Intrinsic Value_5Y_min---603.886--------
Market Cap333022200000.000-9%364224364980.000448079974545.000-19%666794489550.000-45%734899018819.000-50%688054984380.909-47%
Net Profit Margin--0.0930.067+40%0.165-43%0.132-30%0.063+49%
Operating Margin----0%-0%0.061-100%0.002-100%
Operating Ratio--1.7251.699+2%1.478+17%1.493+16%1.583+9%
Pb Ratio4.142-9%4.5305.535-18%8.559-47%11.940-62%11.089-59%
Pe Ratio67.517-9%73.843141.293-48%-237.908+422%26.604+178%22.264+232%
Price Per Share5550.000-9%6070.0007467.500-19%11112.500-45%12247.500-50%11466.818-47%
Price To Free Cash Flow Ratio-75.868+9%-82.97643.397-291%-105.250+27%-188.189+127%-174.714+111%
Price To Total Gains Ratio-201.404+9%-220.274287.360-177%73.034-402%238.335-192%214.491-203%
Quick Ratio--0.9230.646+43%1.112-17%1.629-43%1.534-40%
Return On Assets--0.0130.009+52%0.025-47%0.020-32%0.015-13%
Return On Equity--0.0150.011+39%0.035-56%0.026-41%0.021-25%
Total Gains Per Share---27.55715.549-277%47.129-158%-3.228-88%-1.533-94%
Usd Book Value--56277862.43156680645.376-1%54673423.537+3%45728568.387+23%46995404.666+20%
Usd Book Value Change Per Share---0.0190.011-277%0.033-158%-0.002-88%-0.001-94%
Usd Book Value Per Share--0.9380.945-1%0.911+3%0.762+23%0.783+20%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0140.010+38%0.032-55%0.020-27%0.015-4%
Usd Free Cash Flow---768160.9391013756.592-176%-1932571.893+152%-290333.423-62%-429153.253-44%
Usd Free Cash Flow Per Share---0.0130.017-176%-0.032+152%-0.005-62%-0.007-44%
Usd Free Cash Flow To Equity Per Share---0.0130.017-176%-0.032+152%-0.005-62%-0.002-82%
Usd Market Cap233115540.000-9%254957055.486313655982.182-19%466756142.685-45%514429313.173-50%481638489.067-47%
Usd Price Per Share3.885-9%4.2495.227-19%7.779-45%8.573-50%8.027-47%
Usd Profit--863168.712626147.135+38%1904833.207-55%1174775.429-27%894716.622-4%
Usd Revenue--9247997.8509839791.311-6%10531816.220-12%8313786.140+11%7858022.068+18%
Usd Total Gains Per Share---0.0190.011-277%0.033-158%-0.002-88%-0.001-94%
 EOD+4 -4MRQTTM+14 -18YOY+13 -195Y+8 -2510Y+10 -23

3.2. Fundamental Score

Let's check the fundamental score of Pharmicell based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1567.517
Price to Book Ratio (EOD)Between0-14.142
Net Profit Margin (MRQ)Greater than00.093
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.923
Current Ratio (MRQ)Greater than15.560
Debt to Asset Ratio (MRQ)Less than10.131
Debt to Equity Ratio (MRQ)Less than10.151
Return on Equity (MRQ)Greater than0.150.015
Return on Assets (MRQ)Greater than0.050.013
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Pharmicell based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.023
Ma 20Greater thanMa 505,939.000
Ma 50Greater thanMa 1005,871.400
Ma 100Greater thanMa 2005,877.400
OpenGreater thanClose5,650.000
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Other Current Liabilities  0905,866905,866-159,180746,68667,879814,565-814,5650



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets92,518,753
Total Liabilities12,121,807
Total Stockholder Equity80,396,947
 As reported
Total Liabilities 12,121,807
Total Stockholder Equity+ 80,396,947
Total Assets = 92,518,753

Assets

Total Assets92,518,753
Total Current Assets43,166,152
Long-term Assets49,352,601
Total Current Assets
Cash And Cash Equivalents 13,724,087
Short-term Investments 301,282
Net Receivables 6,865,860
Inventory 20,872,380
Total Current Assets  (as reported)43,166,152
Total Current Assets  (calculated)41,763,609
+/- 1,402,543
Long-term Assets
Property Plant Equipment 40,721,701
Goodwill 5,542,707
Intangible Assets 51,746
Long-term Assets Other 1,273,146
Long-term Assets  (as reported)49,352,601
Long-term Assets  (calculated)47,589,300
+/- 1,763,301

Liabilities & Shareholders' Equity

Total Current Liabilities7,763,157
Long-term Liabilities4,358,650
Total Stockholder Equity80,396,947
Total Current Liabilities
Short Long Term Debt 2,441,976
Accounts payable 1,776,574
Other Current Liabilities 0
Total Current Liabilities  (as reported)7,763,157
Total Current Liabilities  (calculated)4,218,550
+/- 3,544,607
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt585,760
Long-term Liabilities Other 1,355
Long-term Liabilities  (as reported)4,358,650
Long-term Liabilities  (calculated)587,115
+/- 3,771,534
Total Stockholder Equity
Retained Earnings 1,091,057
Total Stockholder Equity (as reported)80,396,947
Total Stockholder Equity (calculated)1,091,057
+/- 79,305,890
Other
Capital Stock30,008,482
Common Stock Shares Outstanding 60,004
Net Invested Capital 82,838,923
Net Working Capital 35,402,995
Property Plant and Equipment Gross 54,398,435



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
131,672,515
130,967,851
132,593,162
99,368,849
101,145,418
102,173,897
59,596,327
60,393,079
60,814,330
63,265,983
64,153,400
67,426,747
67,383,228
69,744,383
72,294,679
94,051,626
97,841,355
95,814,779
103,593,612
107,587,764
113,249,950
109,647,189
113,918,504
110,873,509
101,716,279
92,518,753
92,518,753101,716,279110,873,509113,918,504109,647,189113,249,950107,587,764103,593,61295,814,77997,841,35594,051,62672,294,67969,744,38367,383,22867,426,74764,153,40063,265,98360,814,33060,393,07959,596,327102,173,897101,145,41899,368,849132,593,162130,967,851131,672,515
   > Total Current Assets 
0
0
30,615,988
13,919,475
16,413,693
18,741,968
32,778,096
33,706,223
33,925,671
34,652,511
35,817,960
40,248,309
40,833,502
42,939,491
45,092,921
65,664,411
69,326,915
66,523,225
71,673,921
71,301,127
66,466,403
62,363,173
63,596,003
60,486,532
50,686,837
43,166,152
43,166,15250,686,83760,486,53263,596,00362,363,17366,466,40371,301,12771,673,92166,523,22569,326,91565,664,41145,092,92142,939,49140,833,50240,248,30935,817,96034,652,51133,925,67133,706,22332,778,09618,741,96816,413,69313,919,47530,615,98800
       Cash And Cash Equivalents 
0
0
8,136,168
1,631,330
5,209,967
6,727,499
17,236,270
17,170,347
16,156,691
16,704,920
18,733,525
18,017,307
20,884,883
20,938,948
19,973,650
35,316,281
38,881,910
26,211,422
28,215,254
21,008,204
14,033,427
14,358,780
17,875,383
23,411,564
18,676,938
13,724,087
13,724,08718,676,93823,411,56417,875,38314,358,78014,033,42721,008,20428,215,25426,211,42238,881,91035,316,28119,973,65020,938,94820,884,88318,017,30718,733,52516,704,92016,156,69117,170,34717,236,2706,727,4995,209,9671,631,3308,136,16800
       Short-term Investments 
0
0
6,881,467
880,217
797,661
2,715,449
2,074,765
2,099,182
2,112,151
2,118,502
2,160,807
6,073,992
6,078,080
5,011,352
5,015,721
10,018,729
10,021,621
10,032,361
10,032,491
14,412,835
14,423,992
11,601,101
10,633,715
6,935,668
902,856
301,282
301,282902,8566,935,66810,633,71511,601,10114,423,99214,412,83510,032,49110,032,36110,021,62110,018,7295,015,7215,011,3526,078,0806,073,9922,160,8072,118,5022,112,1512,099,1822,074,7652,715,449797,661880,2176,881,46700
       Net Receivables 
8,492,349
7,040,797
10,331,967
6,197,732
5,816,653
5,208,025
6,628,860
6,272,268
5,426,435
7,181,209
8,302,218
9,674,827
7,925,797
10,161,971
11,068,852
11,544,870
9,822,764
9,595,046
15,148,881
15,966,400
17,374,253
10,753,010
7,508,530
6,457,945
6,582,239
6,865,860
6,865,8606,582,2396,457,9457,508,53010,753,01017,374,25315,966,40015,148,8819,595,0469,822,76411,544,87011,068,85210,161,9717,925,7979,674,8278,302,2187,181,2095,426,4356,272,2686,628,8605,208,0255,816,6536,197,73210,331,9677,040,7978,492,349
       Other Current Assets 
968,952
1,587,447
1,095,142
510,761
865,702
797,067
-1
0
0
0
0
0
0
-2,049,581
-2,049,581
-2,049,581
-2,049,581
-2,049,581
-2,049,581
-998,351
-1,565,512
0
270,179
-948,519
917,890
0
0917,890-948,519270,1790-1,565,512-998,351-2,049,581-2,049,581-2,049,581-2,049,581-2,049,581-2,049,581000000-1797,067865,702510,7611,095,1421,587,447968,952
   > Long-term Assets 
0
0
0
0
0
0
26,818,231
26,686,856
26,888,659
28,613,472
28,335,440
27,178,438
26,549,727
26,804,892
27,201,758
28,387,214
28,514,440
29,291,554
31,919,691
36,286,637
46,783,547
47,284,016
50,322,502
50,386,977
51,029,441
49,352,601
49,352,60151,029,44150,386,97750,322,50247,284,01646,783,54736,286,63731,919,69129,291,55428,514,44028,387,21427,201,75826,804,89226,549,72727,178,43828,335,44028,613,47226,888,65926,686,85626,818,231000000
       Property Plant Equipment 
5,884,421
5,897,078
5,727,813
5,729,348
5,578,805
4,568,253
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,037,110
36,837,637
36,845,051
36,926,350
37,592,246
40,721,701
40,721,70137,592,24636,926,35036,845,05136,837,63737,037,110000000000000004,568,2535,578,8055,729,3485,727,8135,897,0785,884,421
       Goodwill 
38,171,154
40,005,395
40,005,395
34,551,014
34,551,014
34,551,014
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,707
5,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,7075,542,70734,551,01434,551,01434,551,01440,005,39540,005,39538,171,154
       Long Term Investments 
0
0
487,102
2,500
2,500
2,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000002,5002,5002,500487,10200
       Intangible Assets 
38,414,490
40,235,512
225,730
223,796
212,207
207,111
1,134,331
1,082,534
1,565,396
1,513,728
1,637,675
1,575,877
1,514,876
762,280
928,945
1,944,881
2,090,221
693,603
672,172
654,438
638,019
615,862
610,957
600,496
590,122
51,746
51,746590,122600,496610,957615,862638,019654,438672,172693,6032,090,2211,944,881928,945762,2801,514,8761,575,8771,637,6751,513,7281,565,3961,082,5341,134,331207,111212,207223,796225,73040,235,51238,414,490
       Long-term Assets Other 
0
0
0
0
0
0
1,313,833
1,279,050
1,276,244
1,288,388
1,292,731
1,307,365
1,151,365
1,226,463
1,226,284
1,287,944
1,288,175
1,294,060
1,301,797
1,488,224
1,480,052
1,312,792
148,179
138,000
127,820
1,273,146
1,273,146127,820138,000148,1791,312,7921,480,0521,488,2241,301,7971,294,0601,288,1751,287,9441,226,2841,226,4631,151,3651,307,3651,292,7311,288,3881,276,2441,279,0501,313,833000000
> Total Liabilities 
32,269,446
32,352,611
32,303,614
16,948,034
14,948,607
17,902,801
11,140,872
10,809,221
11,333,016
11,746,853
11,777,596
12,074,605
11,308,380
12,639,165
13,295,396
32,878,722
33,092,978
30,461,553
28,906,336
28,996,089
30,774,252
32,982,274
33,472,035
29,877,976
19,665,825
12,121,807
12,121,80719,665,82529,877,97633,472,03532,982,27430,774,25228,996,08928,906,33630,461,55333,092,97832,878,72213,295,39612,639,16511,308,38012,074,60511,777,59611,746,85311,333,01610,809,22111,140,87217,902,80114,948,60716,948,03432,303,61432,352,61132,269,446
   > Total Current Liabilities 
28,475,068
28,488,741
28,248,801
12,831,307
11,078,994
14,018,166
2,756,065
2,272,672
2,719,988
5,526,912
5,588,169
5,856,457
4,955,213
6,507,671
7,299,437
26,843,880
26,905,814
24,943,030
23,313,446
23,231,093
24,876,120
28,546,176
28,911,636
25,226,253
14,851,291
7,763,157
7,763,15714,851,29125,226,25328,911,63628,546,17624,876,12023,231,09323,313,44624,943,03026,905,81426,843,8807,299,4376,507,6714,955,2135,856,4575,588,1695,526,9122,719,9882,272,6722,756,06514,018,16611,078,99412,831,30728,248,80128,488,74128,475,068
       Short-term Debt 
0
0
23,371,074
8,841,166
7,699,294
11,743,683
0
0
0
3,000,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000003,000,00000011,743,6837,699,2948,841,16623,371,07400
       Short Long Term Debt 
0
0
23,371,074
8,841,166
7,699,294
11,743,683
0
0
0
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
3,000,000
15,532,879
16,290,575
17,048,270
17,789,494
18,564,675
19,467,262
16,680,483
16,971,386
15,699,389
4,341,149
2,441,976
2,441,9764,341,14915,699,38916,971,38616,680,48319,467,26218,564,67517,789,49417,048,27016,290,57515,532,8793,000,0003,000,0003,000,0003,000,0003,000,0003,000,00000011,743,6837,699,2948,841,16623,371,07400
       Accounts payable 
1,841,506
2,333,502
2,618,770
1,950,621
1,491,116
775,183
1,129,312
572,695
1,038,304
600,132
621,613
1,086,470
620,597
1,971,838
2,535,857
1,907,168
1,663,634
837,767
1,901,374
2,327,193
3,277,500
2,655,621
2,934,011
1,836,261
2,577,941
1,776,574
1,776,5742,577,9411,836,2612,934,0112,655,6213,277,5002,327,1931,901,374837,7671,663,6341,907,1682,535,8571,971,838620,5971,086,470621,613600,1321,038,304572,6951,129,312775,1831,491,1161,950,6212,618,7702,333,5021,841,506
       Other Current Liabilities 
1,817,382
3,029,147
1,482,725
1,368,236
1,259,331
1,161,129
0
1
0
0
1
0
1
0
1
-1
1
0
1
881,682
832,880
0
905,866
746,686
814,565
0
0814,565746,686905,8660832,880881,682101-11010100101,161,1291,259,3311,368,2361,482,7253,029,1471,817,382
   > Long-term Liabilities 
0
0
0
0
0
0
8,384,807
8,536,549
8,613,028
6,219,941
6,189,427
6,218,148
6,353,167
6,131,494
5,995,960
6,034,841
6,187,164
5,518,523
5,592,890
5,764,995
5,898,132
4,436,098
4,560,399
4,651,723
4,814,534
4,358,650
4,358,6504,814,5344,651,7234,560,3994,436,0985,898,1325,764,9955,592,8905,518,5236,187,1646,034,8415,995,9606,131,4946,353,1676,218,1486,189,4276,219,9418,613,0288,536,5498,384,807000000
       Capital Lease Obligations Min Short Term Debt
0
0
-23,371,074
-8,841,166
-7,699,294
-11,743,683
0
156,604
117,622
-2,919,883
190,933
148,993
106,760
65,653
224,419
162,016
185,058
199,814
292,891
224,989
231,927
163,658
258,373
189,083
231,592
585,760
585,760231,592189,083258,373163,658231,927224,989292,891199,814185,058162,016224,41965,653106,760148,993190,933-2,919,883117,622156,6040-11,743,683-7,699,294-8,841,166-23,371,07400
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
-1
0
-1
0
0
0
0
0
0
0
0
419,644
396,456
1,355
345,739
324,026
302,292
1,355
1,355302,292324,026345,7391,355396,456419,64400000000-10-100000000
       Deferred Long Term Liability 
0
0
52,194,626
41,796,707
41,744,716
41,899,893
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000041,899,89341,744,71641,796,70752,194,62600
> Total Stockholder Equity
99,437,176
98,649,005
100,322,658
82,455,342
86,232,378
84,271,017
48,455,455
49,583,859
49,481,314
51,519,130
52,375,804
55,352,142
56,074,848
57,105,218
58,999,283
61,172,904
64,748,377
65,353,226
74,687,276
78,591,675
82,475,697
76,664,915
80,446,470
80,995,533
82,050,454
80,396,947
80,396,94782,050,45480,995,53380,446,47076,664,91582,475,69778,591,67574,687,27665,353,22664,748,37761,172,90458,999,28357,105,21856,074,84855,352,14252,375,80451,519,13049,481,31449,583,85948,455,45584,271,01786,232,37882,455,342100,322,65898,649,00599,437,176
   Common Stock
20,934,353
21,042,560
21,042,560
21,702,660
22,564,181
22,564,181
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000022,564,18122,564,18121,702,66021,042,56021,042,56020,934,353
   Retained Earnings 
2,804,569
1,592,303
-57,269,168
-80,136,482
-82,504,320
-85,581,826
-170,511,922
-169,383,518
-169,486,063
-167,448,247
-166,591,572
-163,615,235
-162,892,529
-161,862,158
-159,279,142
-157,105,521
-153,530,048
-152,925,198
-147,987,189
-144,735,750
-140,851,727
-146,850,113
1,678,298
2,289,852
3,379,427
1,091,057
1,091,0573,379,4272,289,8521,678,298-146,850,113-140,851,727-144,735,750-147,987,189-152,925,198-153,530,048-157,105,521-159,279,142-161,862,158-162,892,529-163,615,235-166,591,572-167,448,247-169,486,063-169,383,518-170,511,922-85,581,826-82,504,320-80,136,482-57,269,1681,592,3032,804,569
   Capital Surplus 00000000000000000000000000
   Treasury Stock00000000000000000000-114,830-114,830-114,830-114,830-114,830-114,830
   Other Stockholders Equity 
0
0
1,592,302
1,592,302
1,592,185
1,842,509
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,842,5091,592,1851,592,3021,592,30200



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue56,227,379
Cost of Revenue-40,735,416
Gross Profit15,491,96315,491,963
 
Operating Income (+$)
Gross Profit15,491,963
Operating Expense-54,931,382
Operating Income1,295,997-39,439,420
 
Operating Expense (+$)
Research Development6,544,418
Selling General Administrative2,966,170
Selling And Marketing Expenses0
Operating Expense54,931,3829,510,588
 
Net Interest Income (+$)
Interest Income273,797
Interest Expense-866,883
Other Finance Cost-1,774,026
Net Interest Income1,180,940
 
Pretax Income (+$)
Operating Income1,295,997
Net Interest Income1,180,940
Other Non-Operating Income Expenses0
Income Before Tax (EBT)4,732,0571,295,997
EBIT - interestExpense = -866,883
3,577,984
4,444,867
Interest Expense866,883
Earnings Before Interest and Taxes (EBIT)05,598,940
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax4,732,057
Tax Provision-1,154,074
Net Income From Continuing Ops3,577,9843,577,984
Net Income3,577,984
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-1,180,940
 

Technical Analysis of Pharmicell
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharmicell. The general trend of Pharmicell is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharmicell's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharmicell.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6,780 < 6,790 < 6,950.

The bearish price targets are: 5,310 > 5,290 > 5,290.

Tweet this
Pharmicell Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharmicell. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharmicell Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharmicell. The current macd is -142.17772497.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharmicell price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pharmicell. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pharmicell price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Pharmicell Daily Moving Average Convergence/Divergence (MACD) ChartPharmicell Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharmicell. The current adx is 20.27.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Pharmicell shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Pharmicell Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharmicell. The current sar is 5,746.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pharmicell Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharmicell. The current rsi is 42.02. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Pharmicell Daily Relative Strength Index (RSI) ChartPharmicell Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharmicell. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharmicell price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Pharmicell Daily Stochastic Oscillator ChartPharmicell Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharmicell. The current cci is -60.20533423.

Pharmicell Daily Commodity Channel Index (CCI) ChartPharmicell Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharmicell. The current cmo is -19.12191884.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pharmicell Daily Chande Momentum Oscillator (CMO) ChartPharmicell Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharmicell. The current willr is -80.34188034.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Pharmicell Daily Williams %R ChartPharmicell Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pharmicell.

Pharmicell Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharmicell. The current atr is 242.29.

Pharmicell Daily Average True Range (ATR) ChartPharmicell Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharmicell. The current obv is 63,844,768.

Pharmicell Daily On-Balance Volume (OBV) ChartPharmicell Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharmicell. The current mfi is 21.51.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Pharmicell Daily Money Flow Index (MFI) ChartPharmicell Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharmicell.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Pharmicell Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharmicell based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.023
Ma 20Greater thanMa 505,939.000
Ma 50Greater thanMa 1005,871.400
Ma 100Greater thanMa 2005,877.400
OpenGreater thanClose5,650.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pharmicell with someone you think should read this too:
  • Are you bullish or bearish on Pharmicell? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharmicell? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharmicell

I send you an email if I find something interesting about Pharmicell.


Comments

How you think about this?

Leave a comment

Stay informed about Pharmicell.

Receive notifications about Pharmicell in your mailbox!